Therefore, we propose that a combination targeting both the TPL2/MEK/ERK pathway and the RAS/RAF/MEK/ERK pathway may potentially lead to new therapeutic intervention strategies of ADI prostate cancer (Figure S8). This evidence concerns the gene MAP2K7 and Familial prostate cancer.